Incyclix Bio develops selective small molecule inhibitors targeting cyclin-dependent kinase 2 (CDK2) to control aberrant cell proliferation in advanced cancers. Their lead compound, INX-315, aims to provide effective treatment options for patients with resistant tumor types, including ovarian, breast, and lung cancers.
Funding
$36M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BCFounders
Product
Problem
Many advanced cancers exhibit aberrant cell proliferation, driven by dysregulation of cyclin-dependent kinases (CDKs). Current treatment options may be ineffective in controlling this uncontrolled cell growth, particularly in resistant tumor types. This creates a need for more targeted therapies that can selectively inhibit CDK activity and restore normal cell cycle control.
Solution
Incyclix Bio is developing selective small molecule inhibitors that target cyclin-dependent kinase 2 (CDK2) to address uncontrolled cell proliferation in advanced cancers. Their lead compound, INX-315, is designed to provide a more effective treatment option for patients with resistant tumor types, including ovarian, breast, and lung cancers. By precisely targeting CDK2, INX-315 aims to regain control of the cell cycle and halt the progression of these cancers. The company's approach focuses on precision treatments that specifically target the aberrant proliferation driving many cancers.
Target Audience
The primary target audience includes patients with advanced cancers, particularly those with resistant tumor types such as ovarian, breast, and lung cancers, as well as the oncologists treating these patients.
Features
- INX-315: A potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor.
- Designed to target aberrant cell proliferation in advanced cancers.
- Specifically addresses resistant tumor types, including ovarian, breast, and lung cancers.
- Aims to restore normal cell cycle control.